GILD Stock Price Today (October 2026) — Gilead Sciences, Inc. Analysis & Key Metrics 2026-10-07
Gilead Sciences, Inc. (GILD) is trading at $146.85, up 1.82% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $158.65 (8.0% upside).
- Volatility is low (14.50% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.20% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
GILD Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Gilead Sciences, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $203.45B
P/E Ratio
Forward P/E: 14.80
Revenue Growth
Year over Year
Analyst Target
+8.0% upside potential
Key Investor Questions About GILD
What investors need to know before buying
Based on current market data, GILD presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 48.33)
- Fundamentals say: Mixed signals (nuanced financial profile)
GILD's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for GILD investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $26.25B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, GILD stock traded between $109.66 and $157.29 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 14.50% annualized volatility and β=0.50, the stock exhibits low sensitivity to market moves—making GILD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $152.67, moving +1.4% from the previous trading session.
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
Why Morgan Stanley likes Gilead's HIV prevention play
After sessions with Gilead’s leadership at Morgan Stanley’s 2026 Global Healthcare Conference, the bank reaffirmed its Overweight rating, and one franchise stood out.
Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries?
Gilead Sciences (NasdaqGS:GILD) expanded its royalty-free voluntary licensing of once-yearly lenacapavir for HIV prevention to 120 high-incidence countries. The biopharma group signed a regional agreement with the Pan American Health Organization to widen access to twice-yearly lenacapavir across Latin America and the Caribbean. The PAHO partnership creates a direct pathway for 14 additional countries in the region to obtain lenacapavir for HIV prevention programs. Gilead's broader licensing...
Gilead Strengthens HIV Growth Platform with Expanded Latin America Access
Gilead Sciences, Inc. (NASDAQ:GILD) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru, that were outside Gilead’s existing voluntary […]
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation
Gilead Sciences (NASDAQ:GILD) has expanded six existing royalty-free voluntary licensing agreements to include an investigational once-yearly formulation of lenacapavir for HIV prevention, the company announced. The expanded agreements cover 120 countries with high HIV incidence, primarily low- and lower-middle-income nations.
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances
Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O’Day describing the company as being at an “inflection point in value.” Speaking
Is Gilead Sciences (GILD) Reasonable Given Its Sales Base?
Gilead Sciences has delivered a powerful 5 year run in its share price, and fresh headlines around new research facilities and HIV treatments keep attention firmly on its growth story. With the stock now at US$146.42, the live question for investors is whether that market value lines up with what the business is generating in sales. The share price is up 146.6% over 5 years, which puts real pressure on the current sales base to justify where the stock now trades. The new Foster City research...
Explore More Analysis for GILD
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 22, 2026 (after the close, usually)
Frequently Asked Questions
Common investor questions about Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) is currently trading at $146.85. The RSI (14-day) is at 48.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $158.65 implies 8.0% upside from current levels. Volatility is low at 14.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Gilead Sciences, Inc. (GILD): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 14.80. Price-to-Book is 15.36. Price-to-Sales is 5.96. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering GILD, the consensus price target is $158.65. This represents a 8.0% upside from the current price of $146.85. The range spans from a low target of $123.00 to a high target of $180.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Gilead Sciences, Inc. (GILD) pays a dividend with a current yield of approximately 2.23%. The annualized dividend rate is $3.22 per share. The payout ratio is 43.4%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Sep 15, 2026.
Key risks for Gilead Sciences, Inc. (GILD) investors include: 1. Elevated debt levels (debt-to-equity of 2.23x) which could pressure margins in a rising rate environment. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Gilead Sciences, Inc.'s (GILD) current debt and financial health profile: Total debt stands at $26.25B. The debt-to-equity ratio is 2.23x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.27, indicating adequate short-term liquidity. The quick ratio is 0.90. The company holds $4.88B in cash and equivalents. Free cash flow is positive at $9.77B, providing a cushion for debt servicing and shareholder returns.